CNX Therapeutics to invest £2.3bn in Inflexion.

CNX Therapeutics, a distributor of neurological, psychiatric, and emergency hospital treatments, and partners with pharma companies for pan-European coverage to invest £2.3bn in Inflexion, a mid-market private equity firm, investing in established high growth businesses for a minority or majority stake. “We’re incredibly grateful to our existing and new investors for their continued support, as well as the outstanding management teams at Aspen, CNX, Rosemont and Ocorian. We’re excited about the road ahead and look forward to continuing to deliver growth across these four companies in the years to come." George Collier, Inflexion Chief Operating Officer.